By Anna Rose Welch, Director, Cell & Gene Collaborative
Subscribe to my blog ARW on CGT here!
Earlier this year, I attended a press conference with several executives from Pfizer’s Essential Health (PEH) biosimilar business unit. I always enjoy opportunities to learn firsthand how companies that have traditionally been on the innovator side are putting their efforts toward bringing biosimilars to market. Pfizer has been on my radar in particular, not only because it’s one of the first companies to market a biosimilar in the U.S., but also because it’s playing an active role in calling attention to the payer-contracting-related efforts barring biosimilars from the market.
During the hour-long press meeting, company executives shared a few key updates related to Inflectra’s uptake and Pfizer’s ongoing efforts to work with commercial payers. These updates not only shed more light on Inflectra’s market journey, but also reassured me that progress is being made — even though it’s not regularly broadcast in headlines.